Opendata, web and dolomites

PICARD

Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICARD project word cloud

Explore the words cloud of the PICARD project. It provides you a very rough idea of what is the project "PICARD" about.

nature    picard    drug    paying    company    stream    eth    break    payments    costly    assays    reducing    activation    cover    pharmaceutical    fee    estimate    vital    platform    outsourcing    diseases    services    successfully    designed    profiles    drugs    selective    therapeutics    detection    market    gpcrs    efficient    biotech    custom    signalling    roi    biological    lowering    reaching    inefficiencies    receptors    fte    companies    investment    fail    commercialization    fast    class    service    price    clinical    gt    milestone    paul    biology    mechanisms    novelty    risks    efficacy    time    2b    off    lies    interax    5000    inflates    variety    revenue    discovery    leaving    scherrer    45    safety    screening    central    implicated    protein    375    identification    trials    80    stages    candidates    patients    combination    society    gpcr    functional    disease    human    earlier    swiss    uuml    play    coupled    spin    compounds    upfront       pharmacologically    trial    quality   

Project "PICARD" data sheet

The following table provides information about the project.

Coordinator
INTERAX BIOTECH AG 

Organization address
address: PARK INNOVAARE
city: VILLINGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.interaxbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INTERAX BIOTECH AG CH (VILLINGEN) coordinator 50˙000.00

Map

 Project objective

InterAx Biotech, a Swiss company and spin-off from the ETH Zürich and the Paul Scherrer Institute has built PICARD, a unique drug discovery platform for the identification of drug candidates with improved efficacy and reduced side effects for the largest class of human receptors: The G-Protein Coupled Receptors (GPCRs). These receptors play a central role in many vital biological processes and they are implicated in a large variety of human diseases. Due to their complex nature and mechanisms that lead to the disease state, only 60 out of 375 pharmacologically relevant GPCRs have been successfully targeted by drugs, leaving >80% GPCRs without therapeutics. Bringing a drug to the market requires an investment of up to €2.2B; out of 5000 compounds only 5 will make it to the clinical trial phase and 9 out of 10 compounds fail during costly clinical trials. This inflates the price of the drugs that reach the patients, making the society paying for inefficiencies of pharmaceutical R&D. PICARD will enable better and earlier detection of safety and efficacy profiles of GPCR-targeting drugs by increasing quality and reducing costs and time-to-market of new therapeutics. The novelty of our discovery platform lies on the combination of our screening to find novel compounds, signalling Assays that cover the most common GPCR activation aspects and our Systems Biology approach leading to highly efficient and fast delivery of functional-selective compounds. We offer custom-designed PICARD services to pharmaceutical and biotech companies that are outsourcing key stages of their drug discovery process lowering risks and greatly reducing R&D costs. The revenue stream is generated both from fee per service and from long-term drug discovery partnerships with upfront and milestone payments. We estimate reaching break-even 2 years after commercialization with 45 FTE and achieving a ROI of 4.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More